SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Welsh Robert)
 

Search: WFRF:(Welsh Robert) > Clinically signific...

  • Ohman, E. MagnusDuke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. (author)

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1) : a double-blind, multicentre, randomised trial

  • Article/chapterEnglish2017

Publisher, publication year, extent ...

  • 2017
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-322520
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-322520URI
  • https://doi.org/10.1016/S0140-6736(17)30751-1DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background Dual antiplatelet therapy (DAPT), aspirin plus a P2Y12 inhibitor, is the standard antithrombotic treatment following acute coronary syndromes. The factor Xa inhibitor rivaroxaban reduced mortality and ischaemic events when added to DAPT, but caused increased bleeding. The safety of a dual pathway antithrombotic therapy approach combining low-dose rivaroxaban (in place of aspirin) with a P2Y12 inhibitor has not been assesssed in acute coronary syndromes. We aimed to assess rivaroxaban 2.5 mg twice daily versus aspirin 100 mg daily, in addition to clopidogrel or ticagrelor (chosen at investigator discretion before randomisation), for patients with acute coronary syndromes started within 10 days after presentation and continued for 6-12 months.Methods In this double-blind, multicentre, randomised trial (GEMINI-ACS-1) done at 371 clinical centres in 21 countries, eligible patients were older than 18 years with unstable angina, non-ST segment elevation myocardial infarction (NSTEMI) or ST segment elevation myocardial infarction (STEMI), with positive cardiac biomarkers and either ischaemic electrocardiographic changes or an atherosclerotic culprit lesion identified during angiography. Participants were randomly assigned (1: 1) within 10 days after admission for the index acute coronary syndromes event to either aspirin or rivaroxaban based on a computer-generated randomisation schedule. Randomisation was balanced by using randomly permuted blocks with size of four and was stratified based on the background P2Y12 inhibitor (clopidogrel or ticagrelor) intended to be used at the time of randomisation. Investigators and patients were masked to treatment assignment. Patients received a minimum of 180 days of double-blind treatment with rivaroxaban 2.5 mg twice daily or aspirin 100 mg daily. The choice of clopidogrel or ticagrelor during trial conduct was not randomised and was based on investigator preference. The primary endpoint was thrombolysis in myocardial infarction (TIMI) clinically significant bleeding not related to coronary artery bypass grafting (CABG; major, minor, or requiring medical attention) up to day 390. Primary analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT02293395.Findings Between April 22, 2015, and Oct 14, 2016, 3037 patients with acute coronary syndromes were randomly assigned; 1518 to receive aspirin and 1519 to receive rivaroxaban. 1704 patients (56%) were in the ticagrelor and 1333 (44%) in the clopidogrel strata. Median duration of treatment was 291 days (IQR 239-354). TIMI non-CABG clinically significant bleeding was similar with rivaroxaban versus aspirin therapy (total 154 patients [5%]; 80 participants [5%] of 1519 vs 74 participants [5%] of 1518; HR 1.09 [95% CI 0.80-1.50]; p=0.5840).Interpretation A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor. A larger, adequately powered trial would be required to definitively assess the efficacy and safety of this approach.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Roe, Matthew T.Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. (author)
  • Steg, P. GabrielUniv Paris Diderot, AP HP, DHU FIRE, Paris, France.;INSERM, U1148, Paris, France.;Imperial Coll London, NHLI Royal Brompton Hosp, London, England. (author)
  • James, Stefan K.,1964-Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)stjam367 (author)
  • Povsic, Thomas J.Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. (author)
  • White, JenniferDuke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. (author)
  • Rockhold, FrankDuke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. (author)
  • Plotnikov, AlexeiJanssen Res & Dev, Raritan, NJ USA. (author)
  • Mundl, HardiBayer AG, Wuppertal, Germany. (author)
  • Strony, JohnJanssen Res & Dev, Raritan, NJ USA. (author)
  • Sun, XiangJanssen Res & Dev, Raritan, NJ USA. (author)
  • Husted, SteenAarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark. (author)
  • Tendera, MichalMed Univ Silesia, Div Cardiol 3, Katowice, Poland. (author)
  • Montalescot, GillesGrp Hosp Pitie Salpetriere, Inst Cardiol, Paris, France. (author)
  • Cecilia Bahit, M.INECO Neurociencias Orono, Rosario, Santa Fe, Argentina. (author)
  • Ardissino, DiegoPoliclin San Matteo, Div Cardiol, Pavia, Italy. (author)
  • Bueno, HectorSpanish Natl Ctr Cardiovasc Res, Madrid, Spain. (author)
  • Claeys, Marc J.Univ Antwerp Hosp, Edegem, Belgium. (author)
  • Nicolau, Jose C.Univ Sao Paulo, Med Sch, Heart Inst InCor, Sao Paulo, Brazil. (author)
  • Cornel, Jan H.Noordwest Ziekenhuisgrp Alkmaar & Dutch Network C, Dept Cardiol, Alkmaar, Netherlands. (author)
  • Goto, ShinyaTokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa, Japan. (author)
  • Kiss, Robert GaborMil Hosp, Dept Cardiol, Budapest, Hungary. (author)
  • Guray, UmitNumune Educ & Res Hosp, Dept Cardiol, Ankara, Turkey. (author)
  • Park, Duk-WooUniv Ulsan, Coll Med, Asan Med Ctr, Div Cardiol, Seoul, South Korea. (author)
  • Bode, ChristophUniv Freiberg, Freiburg, Germany. (author)
  • Welsh, Robert C.Mazankowski Alberta Heart Inst, Edmonton, AB, Canada.;Univ Alberta, Edmonton, AB, Canada. (author)
  • Gibson, C. MichaelHarvard Med Sch, Beth Israel Deaconess Hosp, PERFUSE Study Grp, Boston, MA USA. (author)
  • Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.Univ Paris Diderot, AP HP, DHU FIRE, Paris, France.;INSERM, U1148, Paris, France.;Imperial Coll London, NHLI Royal Brompton Hosp, London, England. (creator_code:org_t)

Related titles

  • In:The Lancet389:10081, s. 1799-18080140-67361474-547X

Internet link

Find in a library

  • The Lancet (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view